Perindopril Side Effects
Perindopril is generally well tolerated, with cough being the most common side effect (12% of patients), though only 1.3% discontinue therapy because of it. 1
Common Side Effects (≥1% incidence)
Based on FDA labeling from placebo-controlled trials in 1,417 patients, the following adverse events occurred more frequently with perindopril than placebo 1:
Most Frequent:
- Cough: 12% (vs 4.5% placebo) - drug-related in 6%
- Headache: 23.8%
- Upper respiratory infection: 8.6%
- Asthenia (weakness): 7.9%
- Dizziness: 8.2% - dose-dependent, suggesting causal relationship
Other Common Effects (1-6%):
- Back pain: 5.8%
- Sinusitis: 5.2%
- Rhinitis: 4.8%
- Diarrhea: 4.3%
- Edema: 3.9%
- Pharyngitis: 3.3%
- Urinary tract infection: 2.8%
- Abdominal pain: 2.7%
Serious Side Effects (Rare but Important)
Life-Threatening/Serious 1:
- Angioedema: 0.1% - contraindicated if prior history with ACE inhibitors
- Hypotension - particularly in volume-depleted patients
- Hyperkalemia - especially with CKD or potassium-sparing drugs
- Acute renal failure - risk increased with bilateral renal artery stenosis
- Anaphylactic reactions
Other Serious Effects (<1%):
- Cerebrovascular accident: 0.2%
- Myocardial infarction
- Syncope
- Pulmonary fibrosis: <0.1%
- Neutropenia/agranulocytosis
- Hepatic failure, jaundice
- Acute pancreatitis
Laboratory Abnormalities 1
- Hyperkalemia: 1.4% had K+ >5.7 mEq/L
- Renal function: Transient BUN/creatinine elevations (usually minor)
- Liver enzymes: ALT elevation in 1.6%, AST in 0.5% (generally mild and transient)
- Hematology: Small decreases in hemoglobin/hematocrit (rarely clinically significant)
- Leukopenia: 0.1%
Special Populations
Stable Coronary Artery Disease (EUROPA trial, 12,218 patients) 1:
- Discontinuation rate: 22% (similar to placebo)
- Most common reasons for stopping: cough, drug intolerance, hypotension
Combination with Thiazides 1:
- Similar adverse event profile to perindopril alone
- Additional metabolic effects: increased uric acid, triglycerides, cholesterol; decreased potassium
Key Clinical Caveats
Absolute Contraindications 2:
- Never combine with ARBs or renin inhibitors - potentially harmful per ACC/AHA guidelines
- History of angioedema with ACE inhibitors
- Pregnancy (fetal/neonatal morbidity and mortality)
High-Risk Situations:
- Bilateral renal artery stenosis (acute renal failure risk)
- Volume depletion (first-dose hypotension)
- CKD with potassium supplements or K+-sparing drugs (hyperkalemia)
- Severe aortic stenosis
Monitoring Requirements:
- Serum potassium and creatinine, especially in CKD patients
- Blood pressure (watch for excessive drops)
- Complete blood count if infection develops (neutropenia risk)
Comparative Tolerability
When combined with amlodipine, perindopril may attenuate peripheral edema caused by the calcium channel blocker 3, 4. The overall discontinuation rate due to adverse events (6.5%) is similar to placebo (6.7%) 1, confirming excellent tolerability in real-world use.